✦ LIBER ✦

CD31 Expression in Benign, Borderline, and Malignant Epithelial Ovarian Tumors: An Immunohistochemical and Serological Analysis

✍ Scribed by Emile Darai; Annie-France Bringuier; Francine Walker-Combrouze; Arnaud Fauconnier; Anne Couvelard; Gérard Feldmann; Patrick Madelenat; Jean-Yves Scoazec

Book ID: 112247468
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 387 KB
Volume: 71
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.1998.5118

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phenotypic analysis of ovarian carcinoma

Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumors

✍ Ayodele A. Alaiya; Bo Franzén; Kaoru Fujioka; Birgitta Moberger; K. Schedvins; C 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 189 KB 👁 2 views

Expression of human telomerase subunits

Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors

✍ Satoru Kyo,; Taro Kanaya; Masahiro Takakura; Masaaki Tanaka; Atsuko Yamashita; H 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB 👁 2 views

Telomerase activity is involved in the maintenance of telomere length and is thought to be required for cellular immortality and oncogenesis. Three major subunits composing telomerase, human telomerase RNA (hTR), telomeraseassociated protein (TP1) and human telomerase catalytic subunit (hTERT), have

Occurrence of epidermal growth factor re

Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study

✍ S. C. Henzen-Logmans; M. E. L. van der Burg; J. A. Foekens; P. M. J. J. Berns; R 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 753 KB

A review of p53 expression and mutation

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

✍ Leanne M. Kmet; Linda S. Cook; Anthony M. Magliocco 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

## Abstract ## BACKGROUND In the current study, the authors present pooled data from studies that investigated p53 protein expression and/or mutation in human epithelial ovarian tumors. ## METHODS The English literature in the MEDLINE, PubMed, and Ingenta databases was searched to the end of the

EXPRESSION OF MÜLLERIAN INHIBITING SUBST

EXPRESSION OF MÜLLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR PROTEIN AND MRNA IN BENIGN, BORDERLINE, AND MALIGNANT OVARIAN TUMOR

✍ K. Cheon 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Expression of urokinase-type plasminogen

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

✍ Maria E. L. van der Burg; Sonja C. Henzen-Logmans; Els M. J. J. Berns; Wim L. J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 620 KB

Elevated levels of expression of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 have shown to be related to poor prognosis in a variety of cancer types. In the present study, cytosolic levels of uPA and PAI-1 were determined with enzyme-linked immunosorbent assays in cytosols